Локрен Drug photo

The description is actual on 06.10.2014

  • Latin name: Lokren
  • ATH code: C07AB05
  • Active ingredient: Betaksolol (Betaxolol)
  • Producer: Sanofi-Winthrop Industrie (France)


Contains in one tablet of drug active component of a betaksolol – 20 mg. Additional substances: amylopectin sodium glycollate, magnesium stearate, MKTs, gipromelloza, colloid anhydrous silicon dioxide, macrogoal, lactoses monohydrate.

Release form

The medicine is let out in the tableted form. The aluminum blister contains 14 tablets. In a cardboard pack there are 2 blisters (28 tablets).

Pharmacological action

Lokren is beta adrenoblocker. The mechanism of action of a medicine consists in blockade of beta1-adrenoceptors. In addition Lokren possesses membranostabiliziruyushchy activity, without making at the same time simpatomimichesky impact. Pharmacological effects of a medicine:

  • anti-anginal;
  • hypotensive;
  • antiarrhytmic.

Medicine is capable to reduce sensitivity of fabrics to catecholamines, to reduce indicators of ChSS and contractility of a myocardium, to oppress secretion of a renin. Also the medicine prevents increase of the ABP at a stress and exercise stresses.

Pharmacodynamics and pharmacokinetics

After reception the medicine quickly, is completely soaked up from a gastrointestinal tract. The maximum concentration in blood is reached in two hours (an indicator of biological availability about 85%). Badly passes through a placental and blood-brain barrier, it is moderately liposoluble. Slightly higher than 50% of a betaksolol contact blood proteins. It is metabolized betaksolol in a liver, in the form of metabolites (over 80%) it is removed by kidneys. The elimination half-life makes about 20 hours. At a hemodialysis betaksolol is not removed from a blood-groove. Drug does not cause accustoming.

Indications to use

Means is appointed at primary and secondary hypertensia; for prevention of stenocardia.


  • Printsmetal's stenocardia;
  • heart failure;
  • the expressed bradycardia;
  • individual hypersensitivity to a betaksolol;
  • cardiogenic shock;
  • combination therapy with sultopridy;
  • atrioventricular block;
  • one-time reception of inhibitors of monoaminooxidases;
  • cardiomegaly.

The antihypertensive contains a galactose therefore drug is contraindicated:

  • at a sprue of galactose/glucose or deficit of lactose;
  • inborn galactosemia.

Such diseases and states, as:

contraindications for purpose of a betaksolol are relative.

Side effects

From a nervous system:

From cardiovascular system:

  • bradycardia (sinus form);
  • orthostatic hypotension;
  • lowering of blood pressure;
  • heartbeat;
  • AV blockade;
  • disturbance of functions of a myocardium;
  • stethalgia;
  • manifestation of a vasomotor spasm.

From the alimentary system:

  • taste change;
  • dryness of an oral cavity;
  • abdominal pain;
  • vomiting;
  • lock;
  • nausea;
  • diarrhea.

From respiratory system:

  • nose congestion;
  • bronkho-and laryngospasm.

At purpose of high doses the difficulty of breath at predisposed patients is registered.

From endocrine system:

  • hyperglycemia;
  • hypothyroid state;
  • hypoglycemia.

From sense bodys:

  • morbidity, xerophthalmus;
  • disturbances of visual perception.

Allergic answers are possible.

Seldom are registered:

As a result of laboratory researches antinuclear antibodies which can mask under lupus erythematosus symptomatology sometimes are found. In such cases drug withdrawal Lokren is required.

Application instruction (Way and dosage)

Medicine is taken inside, washing down with water, not chewing. To observe the mode of reception calendar packaging with indications of days of the week facilitates. The daily dose of a medicine makes 20 mg. Treatment is recommended to be stopped gradually, reducing a medicine dose step by step to the minimum indicators. Otherwise the withdrawal develops.

The application instruction of Lokren for patients with pathology of renal system differs a little. So, to patients with a renal failure, appoint an initial dose — 5mg/days. At a liver failure the daily dose does not demand correction. The first 100 hours of therapy betaksololy require special attention from doctors.


At reception of the raised doses of a medicine arise:

  • dizziness;
  • heart failure;
  • bradycardia;
  • arrhythmias;
  • lowering of blood pressure;
  • unconscious state;
  • cyanosis of palms, nails;
  • difficulty of breath;
  • atrioventricular block;
  • ventricular ekstrasistoliya;
  • spasms.

Reception of enterosorbents and the emergency gastric lavage is recommended. At registration of bradycardia or fast falling of the ABP appoint 1 mg of a glucagon. If necessary carry in addition slowly out infusion of an izoprenalin – 25 mkg or Dobutaminum — 10 mkg/kg. At detection of heart failure at the newborn, owing to reception of a betaksolol by mother during pregnancy incubation, immediate hospitalization with long introduction of an izoprenalin and Dobutaminum in high doses under supervision of specialists (the pediatrician, the children's cardiologist, the resuscitator) is required.


At combined use of Lokren with antiarrhytmic means (diltiazem, verapamil, Amiodaronum, quinidine) the risk of development of dysfunction of a myocardium sharply increases. At combined use of drug with floktafeniny the risk of development of arterial hypotonia increases. In response to use of galogensoderzhashchy anesthetics Lokren can weaken compensatory abilities of heart. NPVS, glucocorticoids, the antiacid, enveloping means reduce Lokren's efficiency.

At the combined use of tricyclic antidepressants the ABP sharply falls and orthostatic hypotension forms. At Lokren's use together with dihydropyridine derivatives for patients with heart failure (a latentnoprotekayushchy form), the probability of arterial hypotension increases and the heart decompensation forms. Do not recommend to accept Lokren together with MAO inhibitors.

Storage conditions

To store at temperature condition 15 — 25 degrees, in the dark and dry place.

Terms of sale

Only according to recipe of the doctor.

Period of validity

It is possible to store drug in packaging 5 years.

Special instructions

Patients with a liver failure, and also the patient with disturbances of functions of kidneys (KK is equal to 20 ml/min. and above) do not need dose adjustment of a medicine. In the first days clinical supervision is recommended.

At combined use with hypoglycemic means Lokren is capable to mask hypoglycemia symptoms at patients with a diabetes mellitus. The treating doctor should warn patients about need of control of level of sugar. Lokren people need to apply with care with a diabetes mellitus, a bronkhoobstruktivny syndrome, an atrioventricular block (the I Art.), heart failure, a pheochromocytoma, blood circulation disturbance, psoriasis. In case of carrying out the planned operation, Lokren it is necessary to cancel for 48 h before performance of the general anesthesia.

Drug is not used in pediatrics since this category of patients has no clinical data on safety, efficiency of its use.

Lokren's analogs

The pharmaceutical companies let out many substitutes of Lokren. Structural analogs:

  • Betak;
  • Betalmik;
  • Betakor;
  • Betaksolol.

Lokren's analogs differ at the cost and quality. Warn the doctor about desire to buy substitute, perhaps, correction of the scheme of treatment will be required.


  • Lokren of 20 mg No. 28 of a tabletkisanofa Vintrop Indastri
  • Lokren of 20 mg No. 56 of a tabletkisanofa Vintrop Indastri

Drugstore of IFC

  • Lokren tbl p / about 20 mg No. 56, Sanofi-Winthropfrantion
  • Lokren tbl p / about 20 mg No. 28, Sanofi-Winthropfrantion
to show still


  • Lokren of a tablet coated 20 mg No. 28 Abbott Lab. (Italy)
Section: Cardiovascular
in more detail

Education: Graduated from the Bashkir state medical university majoring in "Medical business". In 2011 gained the diploma and the certificate in Therapy. In 2012 received 2 certificate and the diploma in "Functional diagnosis" and "Cardiology". In 2013 completed courses on "Topical issues of otorhinolaryngology in therapy". In 2014 completed advanced training courses in "A clinical echocardiography" and courses in "Medical rehabilitation".

Experience: From 2011 to 2014 the Policlinic No. 33 Ufa worked as the therapist and the cardiologist in MBUZ. Since 2014 the Policlinic No. 33 Ufa works as the cardiologist and the doctor of functional diagnosis in MBUZ.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Lokren surely consult with the attending physician.